|
1
|
Tesniere A, Panaretakis T, Kepp O, Apetoh
L, Ghiringhelli F, Zitvogel L and Kroemer G: Molecular
characteristics of immunogenic cancer cell death. Cell Death
Differ. 15:3–12. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tesniere A, Apetoh L, Ghiringhelli F, Joza
N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L and Kroemer G:
Immunogenic cancer cell death: A key-lock paradigm. Curr Opin
Immunol. 20:504–511. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kroemer G, Galluzzi L, Kepp O and Zitvogel
L: Immunogenic cell death in cancer therapy. Annu Rev Immunol.
31:51–72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Obeid M, Tesniere A, Ghiringhelli F, Fimia
GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T,
Casares N, et al: Calreticulin exposure dictates the immunogenicity
of cancer cell death. Nat Med. 13:54–61. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Obeid M, Panaretakis T, Joza N, Tufi R,
Tesniere A, van Endert P, Zitvogel L and Kroemer G: Calreticulin
exposure is required for the immunogenicity of gamma-irradiation
and UVC light-induced apoptosis. Cell Death Differ. 14:1848–1850.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Panaretakis T, Joza N, Modjtahedi N,
Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini
M, Froehlich KU, et al: The co-translocation of ERp57 and
calreticulin determines the immunogenicity of cell death. Cell
Death Differ. 15:1499–1509. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Panaretakis T, Kepp O, Brockmeier U,
Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N,
Pierron G, van Endert P, et al: Mechanisms of pre-apoptotic
calreticulin exposure in immunogenic cell death. EMBO J.
28:578–590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krysko DV, Garg AD, Kaczmarek A, Krysko O,
Agostinis P and Vandenabeele P: Immunogenic cell death and DAMPs in
cancer therapy. Nat Rev Cancer. 12:860–875. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aymeric L, Apetoh L, Ghiringhelli F,
Tesniere A, Martins I, Kroemer G, Smyth MJ and Zitvogel L: Tumor
Cell Death and ATP release prime dendritic cells and efficient
anticancer immunity. Cancer Res. 70:855–858. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghiringhelli F, Apetoh L, Tesniere A,
Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G,
Ullrich E, et al: Activation of the NLRP3 inflammasome in dendritic
cells induces IL-1beta-dependent adaptive immunity against tumors.
Nat Med. 15:1170–1178. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garg AD, Krysko DV, Verfaillie T,
Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu
C, Roebroek AJ, et al: A novel pathway combining calreticulin
exposure and ATP secretion in immunogenic cancer cell death. EMBO
J. 31:1062–1079. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martins I, Tesniere A, Kepp O, Michaud M,
Schlemmer F, Senovilla L, Séror C, Métivier D, Perfettini JL,
Zitvogel L and Kroemer G: Chemotherapy induces ATP release from
tumor cells. Cell Cycle. 8:3723–3728. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Martins I, Wang Y, Michaud M, Ma Y,
Sukkurwala AQ, Shen S, Kepp O, Métivier D, Galluzzi L, Perfettini
JL, et al: Molecular mechanisms of ATP secretion during immunogenic
cell death. Cell Death Differ. 21:79–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Srivastava P: Interaction of heat shock
proteins with peptides and antigen presenting cells: Chaperoning of
the innate and adaptive immune responses. Annu Rev Immunol.
20:395–425. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Srivastava P: Roles of heat-shock proteins
in innate and adaptive immunity. Nat Rev Immunol. 2:185–194. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schmitt E, Gehrmann M, Brunet M, Multhoff
G and Garrido C: Intracellular and extracellular functions of heat
shock proteins: Repercussions in cancer therapy. J Leukoc Biol.
81:15–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kepp O, Tesniere A, Schlemmer F, Michaud
M, Senovilla L, Zitvogel L and Kroemer G: Immunogenic cell death
modalities and their impact on cancer treatment. Apoptosis.
14:364–375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bianchi ME and Manfredi AA: High-mobility
group box 1 (HMGB1) protein at the crossroads between innate and
adaptive immunity. Immunol Rev. 220:35–46. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamazaki T, Hannani D, Poirier-Colame V,
Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP,
Freudenberg M, et al: Defective immunogenic cell death of
HMGB1-deficient tumors: Compensatory therapy with TLR4 agonists.
Cell Death Differ. 21:69–78. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fredly H, Ersvær E, Gjertsen BT and
Bruserud O: Immunogenic apoptosis in human acute myeloid leukemia
(AML): Primary human AML cells expose calreticulin and release heat
shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep.
25:1549–1556. 2011.PubMed/NCBI
|
|
21
|
D'Eliseo D, Manzi L and Velotti F:
Capsaicin as an inducer of damage-associated molecular patterns
(DAMPs) of immunogenic cell death (ICD) in human bladder cancer
cells. Cell Stress Chaperones. 18:801–808. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garg AD, Krysko DV, Vandenabeele P and
Agostinis P: Hypericin-based photodynamic therapy induces surface
exposure of damage-associated molecular patterns like HSP70 and
calreticulin. Cancer Immunol Immunother. 61:215–221. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fucikova J, Kralikova P, Fialova A,
Brtnicky T, Rob L, Bartunkova J and Spísek R: Human tumor cells
killed by anthracyclines induce a tumor-specific immune response.
Cancer Res. 71:4821–4833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen HM, Wang PH, Chen SS, Wen CC, Chen
YH, Yang WC and Yang NS: Shikonin induces immunogenic cell death in
tumor cells and enhances dendritic cell-based cancer vaccine.
Cancer Immunol Immunother. 61:1989–2002. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao T, Ren H, Jia L, Chen J, Xin W, Yan
F, Li J, Wang X, Gao S, Qian D, et al: Inhibition of HIF-1α by
PX-478 enhances the anti-tumor effect of gemcitabine by inducing
immunogenic cell death in pancreatic ductal adenocarcinoma.
Oncotarget. 6:2250–2262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Menger L, Vacchelli E, Adjemian S, Martins
I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, et
al: Cardiac glycosides exert anticancer effects by inducing
immunogenic cell death. Sci Transl Med. 4:143ra992012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tesniere A, Schlemmer F, Boige V, Kepp O,
Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault
L, et al: Immunogenic death of colon cancer cells treated with
oxaliplatin. Oncogene. 29:482–491. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Calvet CY, Famin D, André FM and Mir LM:
Electro-chemotherapy with bleomycin induces hallmarks of
immunogenic cell death in murine colon cancer cells.
Oncoimmunology. 3:e281312014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Obeid M, Tesniere A, Panaretakis T, Tufi
R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N,
Flament C, et al: Ecto-calreticulin in immunogenic chemotherapy.
Immunol Rev. 220:22–34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dudek AM, Garg AD, Krysko DV, De Ruysscher
D and Agostinis P: Inducers of immunogenic cancer cell death.
Cytokine Growth Factor Rev. 24:319–333. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bezu L, Gomes-de-Silva LC, Dewitte H,
Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O and Kroemer G:
Combinatorial strategies for the induction of immunogenic cell
death. Front Immunol. 6:1872015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Garg AD, Galluzzi L, Apetoh L, Baert T,
Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R,
Cirone M, et al: Molecular and translational classifications of
DAMPS in immunogenic cell death. Front Immunol. 6:5882015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pol J, Vacchelli E, Aranda F, Castoldi F,
Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J,
Spisek R, et al: Trial Watch: Immunogenic cell death inducers for
anticancer chemotherapy. Onco Immunology. 4:e10088662015.
|
|
34
|
Inoue H and Tani K: Multimodal immunogenic
cancer cell death as a consequence of anticancer cytotoxic
treatments. Cell Death Differ. 21:39–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Franco-Molina MA, Mendoza-Gamboa E,
Zapata-Benavides P, Vera-García ME, Castillo-Tello P, García de la
Fuente A, Mendoza RD, Garza RG, Támez-Guerra RS and
Rodríguez-Padilla C: IMMUNEPOTENT CRP (bovine dialyzable leukocyte
extract) adjuvant immunotherapy: A phase I study in non-small cell
lung cancer patients. Cytotherapy. 10:490–496. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Franco-Molina MA, Mendoza-Gamboa E,
Miranda-Hernández D, Zapata-Benavides P, Castillo-León L,
Isaza-Brando C, Tamez-Guerra RS and Rodríguez-Padilla C: In vitro
effects of bovine dialyzable leukocyte extract (bDLE) in cancer
cells. Cytotherapy. 8:408–414. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Franco-Molina MA, Mendoza-Gamboa E,
Zapata-Benavides P, Castillo-Tello P, Isaza-Brando CE, Zamora-Avila
D, Rivera-Morales LG, Miranda-Hernández DF, Sierra-Rivera CA,
Vera-García ME, et al: Antiangiogenic and antitumor effects of
IMMUNEPOTENT CRP in murine melanoma. Immunopharmacol Immunotoxicol.
32:637–646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Franco-Molina MA, Mendoza-Gamboa E,
Castillo-León L, Tamez-Guerra RS and Rodríguez-Padilla C: Bovine
dialyzable leukocyte extract modulates the nitric oxide and
pro-inflammatory cytokine production in
lipopolysaccharide-stimulated murine peritoneal macrophages in
vitro. J Med Food. 8:20–26. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mendoza-Gamboa E, Franco-Molina MA,
Zapata-Benavides P, Castillo-Tello P, Vera-García ME, Tamez-Guerra
RS and Rodríguez-Padilla C: Bovine dialyzable leukocyte extract
modulates AP-1 DNA-binding activity and nuclear transcription
factor expression in MCF-7 breast cancer cells. Cytotherapy.
10:212–219. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Franco-Molina MA, Mendoza-Gamboa E,
Castillo-León L, Tamez-Guerra RS and Rodríguez-Padilla C: Bovine
dialyzable leukocyte extract protects against LPS-induced, murine
endotoxic shock. Int Immunopharmacol. 4:1577–1586. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zitvogel L, Kepp O, Senovilla L, Menger L,
Chaput N and Kroemer G: Immunogenic tumor cell death for optimal
anticancer therapy: The calreticulin exposure pathway. Clin Cancer
Res. 16:3100–3104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cao C, Han Y, Ren Y and Wang Y:
Mitoxantrone-mediated apoptotic B16-F1 cells induce specific
anti-tumor immune response. Cell Mol Immunol. 6:469–475. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tongu M, Harashima N, Yamada T, Harada T
and Harada M: Immunogenic chemotherapy with cyclophosphamide and
doxorubicin against established murine carcinoma. Cancer Immunol
Immunother. 59:769–777. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Perez CA, Fu A, Onishko H, Hallahan DE and
Geng L: Radiation induces an antitumor immune response to mouse
melanoma. Int J Radiat Biol. 85:1126–1136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nowak P, Abdurahman S, Lindkvist A,
Troseid M and Sönnerborg A: Impact of HMGB1/TLR ligand complexes on
HIV-1 replication: Possible role for flagellin during HIV-1
infection. Int J Microbiol. 2012:2638362012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Skitzki JJ, Repasky EA and Evans SS:
Hyperthermia as an immunotherapy strategy for cancer. Curr Opin
Investig Drugs. 10:550–558. 2009.PubMed/NCBI
|
|
47
|
Shi H, Cao T, Connolly JE, Monnet L,
Bennett L, Chapel S, Bagnis C, Mannoni P, Davoust J, Palucka AK and
Banchereau J: Hyperthermia enhances CTL cross-priming. J Immunol.
176:2134–2141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tamura Y, Peng P, Liu K, Daou M and
Srivastava PK: Immunotherapy of tumors with autologous
tumor-derived heat shock protein preparations. Science.
278:117–120. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Vanaja DK, Grossmann ME, Celis E and Young
CY: Tumor prevention and antitumor immunity with heat shock protein
70 induced by 15-deoxy-delta12,14-prostaglandin J2 in transgenic
adenocarcinoma of mouse prostate cells. Cancer Res. 60:4714–4718.
2000.PubMed/NCBI
|
|
50
|
Chiang CL, Ledermann JA, Rad AN, Katz DR
and Chain BM: Hypochlorous acid enhances immunogenicity and uptake
of allogeneic ovarian tumor cells by dendritic cells to cross-prime
tumor-specific T cells. Cancer Immunol Immunother. 55:1384–1395.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chiang CL, Ledermann JA, Aitkens E,
Benjamin E, Katz DR and Chain BM: Oxidation of ovarian epithelial
cancer cells by hypochlorous acid enhances immunogenicity and
stimulates t cells that recognize autologous primary tumor. Clin
Cancer Res. 14:4898–4907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chiang CL, Coukos G and Kandalaft LE:
Whole tumor antigen vaccines: where are we? Vaccines (Basel).
3:344–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zitvogel L, Apetoch L, Ghiringhelli F and
Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev
Immunol. 8:59–73. 2008. View Article : Google Scholar : PubMed/NCBI
|
